Pharmaron Beijing Co., Ltd. (SHE:300759)

China flag China · Delayed Price · Currency is CNY
27.21
-0.86 (-3.06%)
May 8, 2026, 3:04 PM CST
Market Cap46.12B +25.3%
Revenue (ttm)14.57B +14.7%
Net Income1.69B -9.4%
EPS0.95 -10.0%
Shares Out1.83B
PE Ratio28.66
Forward PE21.34
Dividend0.20 (0.74%)
Ex-Dividend DateJul 4, 2025
Volume36,549,037
Average Volume37,190,869
Open28.18
Previous Close28.07
Day's Range27.17 - 28.25
52-Week Range21.99 - 37.63
Beta0.83
RSI36.98
Earnings DateApr 29, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleot... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 25,088
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300759
Full Company Profile

Financial Performance

In 2025, Pharmaron Beijing's revenue was 14.10 billion, an increase of 14.82% compared to the previous year's 12.28 billion. Earnings were 1.66 billion, a decrease of -7.22%.

Financial Statements